Inflammatory bowel disease

Inflammatory bowel disease (IBD) is often described as an “invisible illness” due to symptoms that aren’t always apparent to others. But for the millions living with the disease, the impact goes beyond physical symptoms. Learn how Johnson & Johnson is helping create a patient community for those dealing with the heavy psychological toll of IBD.

This pro-inflammatory protein is the target of potential Johnson & Johnson medications that could help treat immune-mediated diseases such as psoriasis, inflammatory bowel disease and rheumatoid arthritis.

Her natural curiosity, determination and fascination with science inspired Esi Lamousé, M.D., Ph.D., to pursue a career that’s helped bring innovative therapies for inflammatory bowel disease to patients in need around the world.

These GI conditions sound similar, and they also share some symptoms. But IBS and IBD are distinct disorders—especially when it comes to treatment and the risk of complications.

Inflammatory bowel disease doesn’t have a cure—yet. But the recent FDA approval of a promising medication is the latest in a long line of treatments from Johnson & Johnson that are helping patients with IBD.

Over the past few decades, advances in the study and treatment of this inflammatory bowel disease have rapidly accelerated. We spoke to the experts to learn the latest about managing Crohn’s disease—and what other potential breakthroughs are on the horizon.